|Bid||150.00 x 200|
|Ask||168.80 x 500|
|Day's Range||148.58 - 152.07|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||145.30|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vertex is nearing the end of its journey in cystic fibrosis with likely approval of a triple pill in the next couple of years.
The Vetr crowd on Wednesday downgraded its rating of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) from 5 stars (Strong Buy), issued 15 days ago, to 1 star (Strong Sell). Crowd sentiment at the time ...
The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard